Keratinocyte-specific deletion of SHARPIN induces atopic dermatitis-like inflammation in mice

John P. Sundberg 1*, C. Herbert Pratt 1, Leslie P. Goodwin 1, Kathleen A. Silva 1, Victoria E. Kennedy 1, Christopher S. Potter 1, Anisa Dunham 2, Beth A. Sundberg 1, Harm HogenEsch 1,2

1 The Jackson Laboratory, Bar Harbor, ME, United States of America, 2 Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, United States of America

* john.sundberg@jax.org

Abstract

Spontaneous mutations in the SHANK-associated RH domain interacting protein (Sharpin) resulted in a severe autoinflammatory type of chronic proliferative dermatitis, inflammation in other organs, and lymphoid organ defects. To determine whether cell-type restricted loss of Sharpin causes similar lesions, a conditional null mutant was created. Ubiquitously expressing cre-recombinase recapitulated the phenotype seen in spontaneous mutant mice. Limiting expression to keratinocytes (using a Krt14-cre) induced a chronic eosinophilic dermatitis, but no inflammation in other organs or lymphoid organ defects. The dermatitis was associated with a markedly increased concentration of serum IgE and IL18. Crosses with S100a4-cre resulted in milder skin lesions and moderate to severe arthritis. This conditional null mutant will enable more detailed studies on the role of SHARPIN in regulating NFkB and inflammation, while the Krt14-Sharpin-/- provides a new model to study atopic dermatitis.

Introduction

Spontaneous mutations in SHANK-associated RH domain interacting protein (Sharpin) result in a chronic proliferative dermatitis (allele symbol: cpdm) phenotype in two different strains of laboratory mice (C57BL/KaLawRij-Sharpin cpdm/RijSunJ and CBy.OcB3/Dem-Sharpin Dem) [1, 2]. In the Sharpin cpdm mutant mice, a single base pair deletion was observed resulting in a shift of the open reading frame predicted to cause an early stop codon beginning at position 624 (numbered sequence is based on Ensembl cDNA transcript ENSMUST00000023211). The Sharpin cpdm-Dem mutants there was a C to A transition at position 434 in Exon 1 followed by a 14-bp deletion where the 14-bp deletion disrupted the reading frame resulting in an early stop codon. Western blot analysis confirmed loss of SHARPIN protein resulting in both alleles being null mutations [2].
In both mutant mouse strains, homozygous mutants develop a severe, chronic, autoinflammatory disease, affecting multiple organs but especially the skin, where it is typified by progressive epidermal hyperplasia, marked apoptosis of keratinocytes, and a mixed, primarily eosinophilic, dermal inflammation. Homozygous mutant mice exhibit multi-organ eosinophilic inflammation, defective T_{H1} cytokine production, abnormal T cell development, diminished immunoglobulin isotype switching, splenomegaly, early regression of Peyer’s patches, and an absence of B cell follicles, follicular dendritic cells, and germinal centers in secondary lymph organs [3–5]. This phenotype is consistent in both spontaneous null alleles; however, CBy.OcB3/Dem-Sharpin^{cpdm-Dem} mice have a more rapid onset of symptoms and a shorter lifespan, reflecting strain specific effects [6].

SHARPIN is a highly conserved protein that is widely expressed in cells and tissues of mammalian species. It contains three domains, an amino-terminal coiled-coil (CC) domain, an ubiquitin-like (UBL) domain, and an Npl4 zinc finger (NZF) domain [7–9]. SHARPIN was originally described as a structural component of the postsynaptic density of the excitatory synapse in the rat brain where it interacts with SHANK proteins via its CC domain [10]. More recently, SHARPIN was identified as a component of the linear ubiquitin chain assembly complex (LUBAC) which is required for activation of the NFkB signaling pathway [11–14].

LUBAC is composed of an E3 ubiquitin ligase, RING finger protein 31 (RNF31, also known as HOIP), associated with RanBP-type and C3HC4-type zinc finger-containing protein 1 (RBCK1, also known as HOIL1) and SHARPIN. TNF induced cell death is a driver of the cell death seen in the skin of Sharpin^{cpdm} mice as evidenced by the sensitivity of SHARPIN-deficient cells to TNF-induced necroptosis and the lack of dermatitis in TNF-deficient Sharpin^{cpdm} mice [15, 16] TNFR1 results in recruitment of LUBAC to a signaling complex that initiates NFkB signaling. LUBAC catalyzes the addition of linear ubiquitin chains, connected by Met1 linkages, and OTULIN that is specific for linear ubiquitin chains [17–19]. Preliminary observations of compound mutant mice (Sharpin^{cpdm} and Cyld^{tm1Scs}) suggest that the Sharpin^{cpdm} phenotype may be due to the failure to inactivate CYLD (https://www.biorxiv.org/content/10.1101/2020.01.27.919076v1.full). Genetically determined deficiencies in RNF31 and RBCK1 cause immune deficiency, autoinflammatory disease, and glycogen storage disease in human patients [20–23], whereas absence of OTULIN has been reported in six patients with an autoinflammatory syndrome [24, 25].

Fibroblasts, B cells, and dendritic cells isolated from patients or mice deficient in LUBAC components have decreased NFkB signaling in response to TNF and TLR agonists resulting in decreased activation and secretion of cytokines. These findings seem inconsistent with the inflammatory phenotype of LUBAC-deficient patients and mice. Similarly, the association of autoinflammatory disease with both increased and decreased linear ubiquitination and the coexistence of immunodeficiency and autoinflammation in RNF31- and RBCK1-deficient patients seem contradictory. Fibroblasts from patients multi-organ autoinflammation, immunodeficiency, and amylodectasis due to loss of function mutations in RBCK1 and RNF31 exhibited diminished IL1B- and TNF-induced NFkB activation yet monocytes were hyper-responsive to IL1B [26]. These observations point to tissue and cell-specific roles of factors associated with linear ubiquitination. This is also suggested by the reduced response to IL1B in fibroblasts and increased response in whole blood or monocyte cultures from patients with RBCK1- and RNF31-deficiency [21]. In Sharpin^{cpdm} mice IL1B modulates the cutaneous inflammation [27]. In addition to the role of SHARPIN as a structural component of the excitatory synapse and of LUBAC, SHARPIN suppresses B1-integrin activation [28, 29]. There are many other molecular pathways affected directly and indirectly [15, 16, 30–34].
To date, absence of SHARPIN has not been reported in human patients. However, autosomal defects in LUBAC, which SHARPIN is part of, are associated with autoinflammatory and immunodeficiency diseases in humans [35]. Increased expression of SHARPIN was reported in different types of cancers in human patients and appears to be associated with increased malignant behavior [36–41]. This may be in part due to its role in increasing neovascularization in cancer models [42].

The mechanism of carbon tetrachloride and acetaminophen-induced hepatic cirrhosis in mice was shown to be the effects of reduction of SHARPIN in the liver of treated mice [43] and it may play a role in nonalcoholic steatohepatitis [44].

The complex phenotype affecting multiple organ systems evidenced in Sharpin mutant mice suggests that Sharpin function may vary according to cell type. Many of the studies that detail the biochemical studies of SHARPIN function cited above were done in vitro using immortalized mouse embryonic fibroblast cell cultures. In primary cell cultures SHARPIN deficiency sensitized mouse and human keratinocytes as well as mouse embryonic fibroblasts to TNF-induced apoptosis [15]. We hypothesized that the variation in results was because the mouse Sharpin gene is primarily expressed in keratinocytes not fibroblasts. To investigate this, a conditional Sharpin null (B6(Cg)-Tyr<sup>c-2J</sup> Sharpin<sup>tm1Sun</sup>/Sun) was created that developed large differences in disease severity, anatomic involvement, to normality depending upon which cre-recombinase was used indicating anatomic site specificity.

**Methods and materials**

**Source and management of mice**

All mice were maintained in the humidity, temperature, and light cycle (12:12) controlled vivarium under specific pathogen-free conditions (http://jaxmice.jax.org/genetic_health/health_program.html). Mice were housed in double-pen polycarbonate cages (330 cm<sup>2</sup> floor area) at a maximum capacity of four mice per pen. Mice were allowed free access to autoclaved food (NIH 31, 6% fat; LabDiet 5K52, Purina Mills, St. Louis, MO) and acidified water (pH 2.8–3.2). All work was done with the approval of The Jackson Laboratory Animal Care and Use Committee under approval number 07005.

All mice used in these studies were obtained from or created at The Jackson Laboratory (Bar Harbor, ME). The neo cassette was removed by reciprocal matings between homozygous B6(Cg)-Tyr<sup>c-2J</sup> (stock no. 000058), B6(Cg)-Sharpin<sup>tm1Sun</sup>/Sun to create an albino strain. Mice negative for the neo cassette were bred back to the strain of origin, B6(Cg)-Tyr<sup>c-2J</sup>/J to remove the flp allele and mice heterozygous for Sharpin and flp negative were mated to produce a homozygous colony. B6. Cg-Tg(ACTFLPe)9205Dym/J (stock no. 005703), both homozygous female and male mice, were mated to homozygous female and male B6(Cg)-Tyr<sup>c-2J</sup> Sharpin<sup>tm1</sup>/Sun mice to remove the neo cassette (stock no. 012631). The resulting mice were crossed with BALB/c-Tg(CMV-cre)1Cgn/J (stock no. 003465) or B6.C-Tg(CMV-cre)1Cgn/J (stock no. 006054) to remove Sharpin expression in all cells (ubiquitous expression). In order to only remove Sharpin expression from keratinocytes, B6(Cg)-Tyr<sup>c-2J</sup> Sharpin<sup>tm1Sun</sup>/Sun with the neo removed were crossed with STOCK Tg(KRT14-cre)1Amc/J (stock no. 004782). To eliminate Sharpin expression from adipocytes, hemizygous male B6.FVB-Tg(Adipoq-cre)1Evdr/J (stock no. 010803) mice were mated to female B6(Cg)-Tyr<sup>c-2J</sup> Sharpin<sup>tm1Sun</sup>/Sun. To remove Sharpin from fibroblasts the mice were crossed with BALB/c-Tg(S100a4-cre)1Eng/YunkJ (stock no. 012641). F1 mice, heterozygous for both Sharpin and cre-recombinase, were crossed to produce F2s that were genotyped for Sharpin and for cre-recombinase using the generic cre quantitative QPCR using protocols described on The Jackson Laboratory’s website (http://jaxmice.jax.org) for the respective strain.
Creation of Sharpin conditional null mice

To create a conditional knockout line, a Sharpin conditional targeting vector was generated using standard recombineering techniques [45]. A mini-retrieval vector was prepared using PCR products of 500 bp for the 5’ and 3’ mini homology segments (Sharpin 5’ret-F 5’-GCGGCCGCAACTCAGCAGTGGCTGACAG-3’ and Sharpin 5’ret-R 5’ GGATCC GCTGCACTGGCGTACAG-3’) and Sharpin 3’ret-F 5’-GGATCCAGGCGACCCAGCATAGAA-3’, Sharpin 3’ret-R 5’-CTCGAGTGAGCTCAAGGTTCATGCATG-3’) which contained restriction sites for cloning into pBlight (a plasmid with a MCI_TK cassette downstream of the 3’ retrieval arm, gift of S. Warming [45]). The linearized mini-retrieval vector was used to retrieve 9.6 kb of Sharpin and flanking genomic sequence from BAC RP23-204K8 (Children’s Hospital Oakland Research Institute, Oakland, CA) by gap repair. The retrieved genomic sequence contained the entire Sharpin gene of 4.07 kb including 9 exons of which 8 are coding, as well as 978 bp of Maf1 sequence 5’ of the Sharpin gene, and the 2.1 kb gene sequence for Cyc1 present within the region comprising the 4kb 3’ homology arm. The placement of the frt-PGK-neo-frt cassette was designed to avoid repetitive sequences in intron 2 of Sharpin using the online application RepeatMasker (http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker). Exons 3–9 of the Sharpin gene (3kb) were floxed using loxP sites that were inserted by recombineering. On the 3’ end of exon 9 a floxed neo cassette was engineered that was subsequently exposed to cre-recombinase to leave a single loxP site on the 5’ end of Sharpin exons 3–9. In intron 2, a frt-PGK-neo-frt loxP cassette was inserted by recombineering, to effectively flank functionally essential parts of the gene with loxP sites for removal in a temporal and spatial manner by breeding to a cre-expressing strain. The PGK-neo cassette was flanked by frt sequences to facilitate its removal independent of the loxP. The frt-PGK-neo-frt-loxP cassette was preceded by a 2.3 kB arm of the Sharpin gene sequence. 3’ of the floxed Sharpin exons is 4kb of sequence comprising the 3’ retrieval arm (Fig 1A).

The correct sequence was confirmed by Sanger sequencing. The plasmid was purified using the Midi-prep kit (Qiagen, Valencia, CA).

Plasmid DNA (60 ug) was linearized with SspI precipitated with ethanol and submitted to the Cell Biology Core at The Jackson Laboratory for B6-Tyr embryonic stem (ES) cell electroporation. Stably transfected cells were selected by G418 resistance. A total of 360 B6-Tyr ES cell clones were screened for homologous insertion of the transgene by Southern blot after digestion with DraIII, using as a probe a PCR product (primers Forward 5’- AGCTTGACCTGGCTGAGTTGGTATTGGT -3’ and Reverse 5’- GGAGCCTAGGTTAGCCATGGCATG-3’) whose sequence lay outside of the 5’ homology arm.

Primers used for the detection of Sharpin post flp and post cre were GGGATGTATCTGTCTGGGAAC-mutant, GCCCTTGGAGGCTATTTGTT-common, and GCCCAAGTCTTCCCATCATA-wildtype reverse.

Phenotyping mutant mice

For each comparison conducted in this study, age matched female and male mutant and control mice were collected, euthanized by CO₂ asphyxiation using approved methods, and complete necropsies performed using previously described methods [46]. Briefly, hematoxylin and eosin (H&E) stained slides were examined by experienced board certified veterinary anatomic pathologists (JPS, HH) and all lesions subjectively scored (normal, 0; mild, 1; moderate, 2; severe, 3; extreme, 4) and data (with diagnosis and anatomic site) entered into the Mouse Disease Information Database (MoDIS) [47]. These data were used to generate spreadsheets for semi-quantitative analysis. Morphometric analyses of tissue sections were conducted to determine epidermal thickness (dorsal interscapular skin) along the linear length of sample. In each
case, five measurements were made along an H&E stained section of dorsal skin from each mouse. The thickness of the Malpighian layer (basement membrane to the base of the stratum corneum) was measured in vertical sections (perpendicular to the basement membrane) in which the entire length of the hair follicle was visible in the field to assure consistent

Fig 1. Identification of correctly targeted ES cell clones. Homologous recombination between the Sharpin cko-targeting vector and the Sharpin genomic locus, flanked by Cyc1 and Maf1. The correctly targeted locus is 12kb, when mated to Flpe, the removal of neo will leave a 10.3 kb targeted allele and mating to various cre-recombinase strains will leave 7kb for the Sharpin+/− allele. LoxP sites are depicted by white triangles and frt sites by black triangles (A). Southern blot analysis of the ES cell clones. (B6+/+) Wild-type ES clones; (B6 Sharpin−/−) conditional knockout ES clones. Correctly targeted ES cells (cko allele) have a 5.0-kb DraIII band, the wild type allele shows 8.5 kb band, following hybridization with the 5′ probe (B). Genotyping assay for Sharpin alleles. Primers were designed to discriminate between the Sharpin alleles, WT+/+, het +/-, and null −/−. Arrows point to the expected size band, wild-type or Sharpin−/−. Lane 1 shows molecular weight marker (C). Neo copy Sharpin. A copy number QPCR assay was performed on the various Sharpin alleles. Lane 1 and 2: BL6 Tyr−/− and BALB WT do not contain any neo copies, lane 3–27454 Sharpin het (+/−) post cre, pre Flpe shows a single neo copy, lanes 4 and 5 are homozygous null pre Flpe, and lane 6 is BL6-1 after Flpe mating (D). Sharpin loss of allele (LOA). QPCR LOA assay was performed to detect the presence of absence of the Sharpin exon 4. The first 2 het samples show the loss of a Sharpin allele as compared with the WT sample (E).

https://doi.org/10.1371/journal.pone.0235295.g001
orientation. Stratum corneum was measured immediately above the Malpighian layer. The thicknesses of both layers were added to yield the total epidermal thickness of the sample. Measurements were done manually at 400x magnification using a DP27 digital camera on a BX50F4 photomicroscope (Olympus, Tokyo, Japan) and DP controller 3.2 software (Olympus, Center Valley, PA) by one pathologist (JPS).

**Hematology**

Whole blood (200 μl) was collected in soda lime glass micro-hematocrit capillary tubes (stock no. 51608, Globe Scientific, Paramus, NJ). The uncoagulated blood was run without separation on a Siemens Advia 2120 Hematology Analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY).

**Immunohistochemistry**

To determine where SHARPIN protein was expressed, immunohistochemistry was done using a Ventana XT autostainer (Tuscon, AZ) with an antibody directed against SHARPIN (Sharpin (Y-14) stock no. sc~98129, Santa Cruz, Dallas, TX). Immunohistochemistry was tested using 5 different fixatives. Only 4% paraformaldehyde fixed sections worked with this antibody. For immunohistochemistry, 1 male 121 day old C57BLKaLawRij-Sharpin<sup>cpdm</sup>/Rij-SunJ (null mutant), 1 male 133 day old C57BLKaLawRij/RijSunJ (wildtype control), one 57 day old CBByOcB3-Sharpin<sup>cpdm-Dem</sup>/Sz (null mutant), and 1 CBByOcB3/Sz (wildtype control) had skin collected and fixed in 4% paraformaldehyde. Slides were run using a Ventana Discovery XT autostainer (Ventana, Tuscon, AZ) with diaminobenzidine (Sigma, St. Louis, MO) used as chromogen.

**Quantitative real-time RT-PCR (qRT-PCR) to genotype for Sharpin**

The expression of mRNA in the skin of 4-week old mice was determined by qRT-PCR [48]. Skin from 4 weeks of age/sex matched mice was collected and stored in RNALater (Qiagen, Valencia, CA) at -80°C until samples from all replicates were collected. RNA was then extracted using a PureLink RNA Mini Kit (Invitrogen, Grand Island, NY). For each qRT-PCR, a 15ul reaction was run with 7.5 μl Taqman One-Step RT-PCR Master Mix 2X (Life Technologies, Grand Island, NY), 0.4ul, 40X Multiscribe and Rnase Inhibitor Mix, 0.75 μl of 20X Assays on Demand Taqman primer and probe set and 100ng RNA. The qRT-PCR was performed in a Mastercycler® realplex4 (Eppendorf, Hauppauge, NY) programmed at 40 cycles of 42 C for 50 minutes, 90 C for 10 minutes, 95 C for 15 seconds, 60 C for 1 minute, and 72 C for 1 minute. The Ct values for each chemokine were normalized by subtracting the Ct values for the housekeeping gene Actb (Delta Ct). The relative fold-change in mRNA expression between wild-type mice and mutant mice was calculated by the 2<sup>(-delta-delta Ct)</sup> method [49].

**Localization of gene expression for cre-recombinase transgenic mice**

While a review of the literature can suggest where genes are naturally expressed, it is always important to verify this when various promoters are used with cre-recombinases. To do this, slides were obtained from the Comprehensive cre Characterization Resource at The Jackson Laboratory where whole slide scanned images of embryos (E15.5) or tissues (at P7 and P56) can be viewed online (http://www.informatics.jax.org/home/recombinase) [50]. The slides were created using frozen sections of tissues (or embryos) from crosses between each of the cre-recombinase transgenic mice listed above and B6.129S4-<i>Gt</i> (Rosa) 26Sor<sup>tm1Sor</sup>/J (Stock No. 3474). Fresh frozen sections were labeled as previously described [51].
Serum immunoglobulins and serum IL-18
Concentrations of serum IgM, IgG, IgA, and IgE were determined by ELISA using isotype-specific reagents obtained from Southern Biotech (Birmingham, AL) as previously described [3]). The concentration of IL18 in serum of mice was determined using a commercially available ELISA (MBL International, Woburn, MA).

Cytokines
RNA isolation and analysis from skin samples was done as previously described [52]. Skin samples collected from the left side of mice were homogenized in TRI-reagent (Sigma-Aldrich). Total RNA was isolated by standard TRI-reagent methods according to the manufacturer’s protocols and quantitated at 260 nm. RNA was analyzed by quantitative real time RT-PCR (qPCR) and custom eTags™ multiplex assays (ACLARA Biosciences, Mountain View, CA).

For qPCR, RNA was reverse transcribed for 1 hour at 42˚C in 30μL volumes containing 0.5μg RNA, 2.8U Recombinant RNasin Ribonuclease Inhibitor, 400U M-MLV Reverse Transcriptase, 6.0μL M-MLV Reverse Transcriptase 5X buffer, 0.25μg Oligo(dT) 15 Primer, and 0.5mM of each nucleotide (Promega, Madison, WI) in a Peltier Thermal Cycler 200 (MJ Research/Bio-Rad Laboratories, Waltham, MA). The cDNA was analyzed with Assays on Demand Taqman® primer and probe sets following the manufacturer’s instructions using the 7300 Real Time PCR System and Sequence Detection Software v1.2.1 (Applied Biosystems, Foster City, CA). The Ct values for each chemokine were normalized by subtracting the Ct values for the housekeeping gene actin beta (Actb, ID Mm00607939_s1). The difference in mRNA expression between mice was calculated with the difference in normalized Ct values (fold change = 2^{ΔΔCt}) [49].

Statistical analysis
Graphs and descriptive statistics were generated in GraphPad Prism Version 8.3.1. The statistical significance of differences between means of experimental groups for epidermal thickness, expression of mRNA and protein concentrations was determined by two-tailed Student’s t-test using Microsoft® Excel and GraphPad Prism. Differences were considered significant at p < 0.05.

Results
Creation of the conditional Sharpin allelic mutation
The wild-type Sharpin allele consists of 9 exons, which encode 387 amino acids, producing a 40kd protein (Fig 1). An alternative start site is hypothesized to exist at exon 6 that encodes a 60 kd splice variant (www.ensembl.org). Given the high number of repetitive sequences in intron 2, a targeting vector was constructed in which exons 3–9 were flanked by Frt-neo-Frt-loxp and loxp sites.

Mice positively expressing the new allele that also contained the Frt-neo-Frt-cassette had the latter cassette removed by crossing the mice with by reciprocal matings between homozygous B6(Cg)-Tyr^{−/−} and B6(Cg)-Sharpin^{tm1Sun}/Sun, to create an albino stock, and B6.Cg-Tg(ACTFLPe)9205Dym/J mice (Fig 1). Mice negative for the neo cassette were bred back to the strain of origin, B6(Cg)-Tyr^{−/−} and B6(Cg)-Sharpin^{tm1Sun}/Sun, to remove the flp allele and mice heterozygous for Sharpin and flp negative were mated to produce a homozygous colony. Once viable conditional Sharpin null (B6(Cg)-Tyr^{−/−} Sharpin^{tm1.1Sun}/Sun, hereafter referred to as Sharpin^{−/−}) mice were confirmed, crosses were established with transgenic mice carrying cell specific promoters driving cre-recombinase in order to ubiquitously or selectively inactivate Sharpin.
Expression of SHARPIN protein in various organs

To determine the distribution of SHARPIN protein expression, immunohistochemistry was done on tissues from wild type controls and Sharpin<sup>cpdm</sup> mutant mice. Tissues from the Sharpin<sup>cpdm</sup> null mice were negative (except for endogenous peroxidase activity in a few cells such as mast cells) which served as a negative control. SHARPIN was not expressed in the liver, Peyer’s patches, or intestine. However, SHARPIN was detected in epithelial cells of the skin and hair follicles, foot pad, eccrine gland, tongue, lingual gland, esophagus, hard palate, nasal epithelium, tooth (ameloblasts), nail unit (hyponychium and proximal nail fold), forestomach, cornea and lens of the eye, and Purkinje cells of the cerebellum (Fig 2).

Expression of cre-recombinases in the skin

To verify that the transgenic mice carrying cre-recombinases expressed the cre where it was expected, they were crossed with transgenic mice carrying a LacZ reporter. The CMV ubiquitously expressing cre-recombinase exhibited widespread expression on the BALB/c and C57BL/6 background (data not shown). Krt14-cre transgene was expressed in the epidermis

---

**Fig 2. Immunohistochemical localization of SHARPIN protein.** SHARPIN protein was normally expressed in the epidermis and hair follicles (A) of wild type, control mice (N = 2) but not in the spontaneous chronic proliferative dermatitis (Sharpin<sup>cpdm/cpdm</sup>) null mutant mice (N = 2, B), which served as a negative control. In normal wild type mice SHARPIN was not expressed in the liver (C), Peyer’s patches, or intestine (E). However, SHARPIN was expressed in epithelial cells of the foot pad (D) and eccrine gland (D, I), tongue (F), lingual gland (G), esophagus (H), hard palate (M) and nasal epithelium (M and insert), tooth (ameloblasts) (K), nail unit (hyponychium and proximal nail fold, L, P, Q), forestomach (N), cornea and lens of the eye (O), and Purkinje cells of the cerebellum (J).

[https://doi.org/10.1371/journal.pone.0235295.g002](https://doi.org/10.1371/journal.pone.0235295.g002)
and hair follicles (and other epidermal structures) similar to immunohistochemical localization of KRT14 (S1A Fig) [53]. S100 calcium binding protein A4 (S100A4) is still published as fibroblast-specific protein [54], but the S100-cre transgene was detected in the epidermis and infundibulum of hair follicles (S1B Fig). S100a4-cre transgenic mice exhibited less expression in basal keratinocytes and the base of hair follicles relative to the Krt14-cre mice which probably accounts for the reduced severity when crossed with the inducible Sharpin null mice. The Adipoq-cre transgene was expressed in adipose tissue (S1C Fig). Additional images are available online (http://www.informatics.jax.org/home/recombinase) [50].

**Overall comparisons of phenotypes**

Control mice and all crosses survived until at least 10 weeks of age with exception of the B6-CMV-cre Sharpin^+/−^ mice (hereafter all compound mutants will have cre left out), most of which died by 6 weeks of age. Therefore, most of the comparative studies were done at 6 weeks of age. BALB-CMV Sharpin^+/−^, B6-CMV Sharpin^+/−^, and Krt14 Sharpin^+/−^ mutant mice developed extensive dermatitis similar to the two spontaneous allelic null mutations, Sharpin^{cpdm/cpdm} and Sharpin^{cpdm-Dem/cpdm-Dem} with no sexual dimorphism [1, 2]. The mice had severe pruritus and scratched frequently which led to skin erosions and ulcers necessitating euthanasia at 8–10 weeks of age for the BALB-CMV Sharpin^+/−^ and Krt14 Sharpin^+/−^ mice.

Body weights were measured on at least 5 mice of each genotype, females and males. Males were consistently higher in weight than females. Control mice and mutant mice with no or mild skin lesions gained weight during the 4–10 week of age observation period (S2 Fig). Degree of failure to gain weight reflected the severity of systemic disease in each cross due to loss of Sharpin. The ubiquitously expressing cre-recombinases resulted in the most severe disease and failure to survive or gain weight. Those with primarily skin lesions (Krt14 cross) were moderately affected. Those with no (Adipoq) or relatively minor lesions, primarily referring to the skin disease (S100a4) were within or at the bottom of the normal range for gain of body weight. The B6-CMV Sharpin^+/−^ mice gained little weight until they died by 6 weeks of age. The BALB-CMV Sharpin^+/−^ mice gained some weight but lagged below the other crosses. The Krt14 Sharpin^+/−^ mice had moderate weight gain but less than the control mice whereas S100a4 Sharpin^+/−^ and Adipoq Sharpin^+/−^ mice were within the normal range for body weight.

Mice carrying the spontaneous Sharpin^{cpdm/cpdm} mutation had marked changes in the peripheral blood white blood cell count and differentials [6]. Changes in the blood confirmed the chronic proliferative dermatitis phenotype in the ubiquitously expressing CMV Sharpin^+/−^ mutant mice on both backgrounds but with a high degree of variability between individuals. However, there was a significant increase of neutrophils in both the Krt14 and S100a4 Sharpin^+/−^ mice, but only eosinophils for the Krt14 Sharpin mutant mice (S3 Fig). As with the spontaneous Sharpin null mice [6], there was no sexual dichotomy. There was no change in the peripheral blood for the Adipoq Sharpin^+/−^ mutant mice.

Epidermal hyperplasia is a hallmark of the chronic proliferative dermatitis phenotype [1, 6] and a useful marker for quantitative assessment of the dermatitis. The thickness of both the Malpighian layer (stratum basale and stratum spinosum) and the stratum corneum in both the B6-CMV Sharpin^+/−^ and BALB-CMV Sharpin^+/−^ mutant mice was significantly greater than the controls, similar to that found the two spontaneous allelic null mutations (Sharpin^{cpdm/cpdm} and Sharpin^{cpdm-Dem/cpdm-Dem}) (Fig 3) [6]. Krt14 Sharpin^+/−^ mice had a similar increase of epidermal thickness as mice with ubiquitously deleted Sharpin. The S100a4 Sharpin^+/−^ mice had a thicker epidermis than controls but it was significantly less so than the CMV Sharpin^+/−^ and Krt14 Sharpin^+/−^ crosses. There was no difference in epidermal thickness between the Adipoq Sharpin^+/−^ and control mice (Fig 3).
Cre-specific phenotypes

Lesions varied by their presence or absence in different organs as well as the severity in specific organs based on the cre-recombinase used. Lesions were compared with those in the spontaneous null allele Sharpin<sub>cpdm/cpdm</sub> (Table 1). Major lesions are described by each cross and the accompanying figures compare lesions from the same sites for all the crosses.

Fig 3. Changes in epidermal thickness. There was a significant difference in thickness of the stratum basale and stratum spinosum (SB-SSp) and the stratum corneum (SC) between the control mice (WT) and B6-CMV, C-CMV, Krt14, and S100a4 Sharpin<sup>−/−</sup> mutant mice (** p < 0.01). Epidermal thickness was similar in the Krt14 Sharpin<sup>−/−</sup> to those ubiquitously expressing CMV-cre, but less in S100a4 Sharpin<sup>−/−</sup> mice. The Adipoq Sharpin<sup>−/−</sup> mutant mice were unaffected, identical to the controls. Bars represent the mean + SEM of 4–10 mice per group. ND—not done.

https://doi.org/10.1371/journal.pone.0235295.g003
F1 mice heterozygous for both Sharpin and cre-recombinase were crossed to produce F2 mice that were genotyped for Sharpin and for cre using quantitative QPCR. All genotypes were evaluated but only those homozygous for Sharpin\textsuperscript{tm1Sun} and homozygous or heterozygous for the cre-recombinase developed lesions. Results were similar in mice carrying one or both copies of the cre-recombinase.

B6(Cg)-\textsuperscript{Tyr}-\textsuperscript{c2J} Sharpin\textsuperscript{tm1Sun}/Sun mice recapitulate the cpdm phenotype when crossed to mice ubiquitously expressing cre-recombinase. Conditional Sharpin null mice were crossed with a CMV ubiquitously expressing cre-recombinase on two different genetic backgrounds. The BALB/c transgenic line was initially available, which resulted in a hybrid stock, potentially complicating interpretation of the phenotype. When the B6 transgenic line became available this construct was also used.

Lesions were largely similar to what has been earlier described in Sharpin\textsuperscript{cpdm/cpdm} and Sharpin\textsuperscript{cpdm-Dem/cpdm-Dem} mice with the spontaneous null mutation \cite{1, 6, 55}. The mice had prominent skin lesions (Fig 4). The epidermis contained scattered apoptotic keratinocytes (arrow, Fig 4E) and was significantly increased in thickness as a result of acanthosis and ortho- and parakeratotic hyperkeratosis (Fig 3). There was inflammation of the dermis comprised of accumulations of granulocytes and macrophages. Eosinophils were also present in the epidermis and occasionally formed intracorneal and subcorneal pustules. There were increased numbers of cross-sections of small blood vessels in the dermis as found in the spontaneous mutants \cite{56}. The dermis of older mice had an increase of collagen deposition (fibrosis).

There was moderate to severe hyperplasia of the epithelium of the esophagus with scattered apoptotic epithelial cells (data not shown). The cornified layer of the epithelium was thickened and there was accumulation of eosinophils in the subepithelial propria mucosae and the basal layer of the epithelium. Changes were similar to those described in Sharpin\textsuperscript{cpdm/cpdm} mice \cite{57}. Changes in the forestomach varied from the presence of a few apoptotic epithelial cells to marked and diffuse thickening of the epithelium (S4 Fig). A few inflammatory cells, mostly eosinophils, were present in the subepithelial connective tissue. Mild hyperplasia and a few apoptotic epithelial cells were observed on the epithelium of the oral cavity. These changes resemble those found in the spontaneous mutant mice \cite{57}.

There was mild to extensive inflammation in the portal areas and surrounding the central veins of the liver (S5 Fig), and around the bronchioles and blood vasculature of the lungs (S6 Fig). The inflammation in the liver consisted mostly of a mixed population of granulocytes and macrophages with mild fibrosis. In the lungs, the majority of cells were lymphocytic with fewer granulocytes and macrophages. Inflammatory changes were observed in the joints of some mice (S7 and S8 Figs). The most severely affected joint was the humeroscapular (shoulder joint) with accumulation of granulocytes in the synovial membrane and surrounding tissues and fibrosis. Milder changes were seen in the knee joints. Similar inflammatory changes were observed in the middle ear (S9 Fig).

### Table 1. Histologic lesions in wild type and mutant 6 week old mice. Note variation in lesion distribution and severity based on where SHARPIN was deleted.

| Strain                  | Skin  | Forestomach | Liver | Lung  | Shoulder | Knee | Middle Ear | Peyer’s Patch | Spleen | Lymph Node |
|-------------------------|-------|-------------|-------|-------|----------|------|------------|---------------|--------|------------|
| Sharpin\textsuperscript{+/-} | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal |
| Sharpin\textsuperscript{cpdm/cpdm} | Severe | Severe | Severe | Severe | Severe | Severe | Severe | Severe | Severe | Severe |
| BALB-CMV-cre Sharpin\textsuperscript{+/-} | Severe | Severe | Severe | Mild | Variable | Minimal | Severe | Missing | Severe | Severe |
| B6-CMV-cre Sharpin\textsuperscript{+/-} | Severe | Severe | Severe | Severe | Normal | Mild | Severe | Missing | Severe | Severe |
| Krt14-cre Sharpin\textsuperscript{+/-} | Severe | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal |
| S100a4-cre Sharpin\textsuperscript{+/-} | Mild | Normal | Normal | Severe | Severe | Mild | Normal | Normal | Normal | Mild |
| Adipoq-cre Sharpin\textsuperscript{+/-} | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal |

https://doi.org/10.1371/journal.pone.0235295.1001
Fig 4. Dorsal skin histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin null gene were normal (A). Normal epidermis was thin with few, if any inflammatory cells in the dermis. However, mice carrying one or two copies of the ubiquitously expressing CMV-cre
Similar to Sharpin<sup>cpdm/cpdm</sup> mice, in both of the CMV-cre Sharpin<sup>−/−</sup> strains there was a nearly complete loss of lymphoid tissues in the small and large intestine (S10 Fig). In younger mice, small aggregates of lymphocytes often mixed with granulocytes, mostly eosinophils (confirmed using eosinophilic major basic protein by immunohistochemistry, data not shown), could occasionally be found in the submucosa and lamina propria of the small and large intestine. These represent remnants of the Peyer’s patches and large intestinal follicles following a process of involution as previously described [5].

Well-defined lymphoid follicles were absent from the white pulp of the spleen and from lymphoid follicles. There was a mild to moderate increase of myelopoiesis in the red pulp (S11 Fig). There was marked lymphoid depletion with effacement of the lymph node by eosinophils in the spontaneous and ubiquitously deleted Sharpin null mice (S12 Fig). The thymus of Sharpin<sup>cpdm/cpdm</sup> mice was often smaller in size, but maintained a well populated cortex which was clearly separated from the medulla. By contrast, mild to severe involution of the thymus was present in CMV-cre mice. In the mildly affected mice, the overall thymus was markedly reduced in size, but there was a clearly defined cortex that was densely populated with thymocytes. In more advanced lesions, there was a marked increase of apoptosis of thymocytes in both the cortex and medulla. In the most advanced lesions, a single remnant of the thymus could be identified consisting of a small sheet of epithelial cells with few lymphocytes. Cysts lined by ciliated epithelial cells were present in the thymic remnant of one mouse.

Krt14-cre-recombinase mice. No lesions were observed in the control mice. The epidermis of Krt14 Sharpin<sup>−/−</sup> mice contained numerous apoptotic keratinocytes and had marked acanthosis and ortho- and parakeratotic hyperkeratosis resulting in a significant increase of epidermal thickness (Figs 3 and 4E). The increased epidermal thickness was similar to that seen in the spontaneous and ubiquitously deleted Sharpin mutant mice. There was abundant mixed cellular inflammation in the dermis. Granulocytes, both eosinophils and neutrophils, were common in the dermis and epidermis and frequently formed intracorneal or subcorneal microabscesses. There were occasional apoptotic epithelial cells in the oral mucosa with mild acanthosis and focal areas of parakeratotic hyperkeratosis. A few granulocytes were present in the subepithelial propria mucosae and in the epithelium. No changes were observed in the mucosa of the esophagus or forestomach (S4E Fig) in contrast to Sharpin<sup>cpdm/cpdm</sup> mice with generalized deletion of the SHARPIN protein. Lymphoid tissues appeared normal including the presence of Peyer’s patches in the small intestine (S10E Fig) and well-defined lymphoid follicles in lymph nodes (S12E Fig) and spleen (S11E Fig). There was a mild increase of extracellular hematopoiesis, primarily myelopoiesis, in the red pulp of the spleen of a few mice (S11E Fig). No evidence of inflammation was present in the liver (S5E Fig), lungs (S6E Fig), joints (S7E and S8E Figs) or middle ears (S9E Fig) of Krt14 Sharpin<sup>−/−</sup> mice at 4, 6, and 8 weeks of age. However, one 10-week-old female mouse had severe inflammation characterized by accumulation of granulocytes and macrophages with fibrosis around central veins and in portal areas. There were no lesions in the lungs or joints in this mouse.

S100a4-cre-recombinase mice. No lesions were observed in the control mice. The epidermis of S100a4 Sharpin<sup>−/−</sup> mice contained apoptotic keratinocytes and had various degrees of acanthosis and orthokeratotic hyperkeratosis resulting in mild to moderate increase of epidermal
thickness (Figs 3 and 4F) which were less severe than seen in the ubiquitously deleted \textit{Sharpin} or \textit{Krt14 Sharpin}^{+/+} mice. Mild to moderate mixed cellular inflammation was present in the dermis with occasional presence of inflammatory cells in the epidermis. By contrast to \textit{Sharpin}^{cpdm/cpdm} or CMV \textit{Sharpin}^{+/+} mice with generalized deletion of the SHARPIN protein, lymphoid tissues appeared normal including the presence of Peyer’s patches in the small intestine (S10F Fig) and well defined lymphoid follicles in lymph nodes (S12F Fig) and spleen (S11F Fig). There was a mild to moderate increase of extracellular hematopoiesis and primarily myelopoiesis in the red pulp of the spleen. The shoulder (humeroscapular) joints of 15 of the 16 mice in which this joint could be evaluated had severe arthritis characterized by accumulation of fibrin in the joint space and infiltration of the synovia and surrounding tissues by granulocytes and macrophages (S7F Fig). Fibrotic changes were occasionally observed. There was no light microscopic evidence of damage to the articular cartilage. Mild to moderate arthritis and tendinitis was present in the knee joints of 10 mice. There was also inflammation of the temporomandibular joints in five of 13 mice in which these tissues could be examined (data not shown). The inflammation varied from mild accumulation of granulocytes to the presence of fibrin and numerous granulocytes. No evidence of inflammation was present in the elbow, phalangeal, and intervertebral joints. There was inflammation characterized by accumulation of granulocytes admixed with macrophages in the connective tissue at the base of the heart of four mice, extending into the base of the aorta in two mice. There was mild mixed cellular perivascular and peribronchiolar inflammation in the lungs and inflammation in perportal triads of the liver in one 10-week-old \textit{S100a4 Sharpin}^{+/+} mouse. The lungs (S6F Fig) and liver (S5F Fig) of the other \textit{S100a4 Sharpin}^{+/+} mice had no inflammation.

**Adipoq-cre recombinase mice.** There were no differences noted between the control mice and \textit{Adipoq Sharpin}^{+/+} mice (Fig 3G, S6–S12G Figs).

**Serum immunoglobulins and serum IL18**

Mice with the spontaneous \textit{Sharpin}^{cpdm/cpdm} mutation have a defect in isotype switching resulting in a marked decrease of total serum IgG and IgA, and nearly undetectable IgE (S13 Fig) [3]. \textit{S100a4 Sharpin}^{+/+} mice had similar concentrations of IgG, IgA, and IgE as control mice, and a slightly reduced concentration of IgM (Fig 5). \textit{Krt14 Sharpin}^{+/+} mice had normal...
immunoglobulin concentrations at 4 weeks of age, but significantly increased concentrations of serum IgG and IgE at 10 weeks of age (Fig 5). These data indicate that these mice with selective deletion of Sharpin in non-immune cells did not have a defect in isotype switching and, secondly, demonstrated that the dermatitis in the Krt14 Sharpin<sup>−/−</sup> mice was associated with a marked increase of serum IgE.

IL18 induces an increase of IgE in mice [58], and increased concentration of serum IL18 has been reported in human patients with atopic dermatitis [59, 60]. We therefore determined the concentration of IL18 in the serum of control and mutant mice. There was a significant increase of IL18 in the serum of Sharpin<sup>cpdm/cpdm</sup> mice compared with control mice (Fig 6). A similar increase was observed in the serum of Krt14 Sharpin<sup>−/−</sup> and S100a4 Sharpin<sup>−/−</sup> mice. The concentration increased with the age of the mice and the progression of the dermatitis, and was much higher in the Krt14 Sharpin<sup>−/−</sup> mice than the other mutant strains.

**Cutaneous expression of cytokines and proteases**

The spontaneous Sharpin<sup>cpdm/cpdm</sup> null mice developed a persistent dermatitis associated with increased expression of TH2 cytokines, chitinase-like 3 protein (CHIL3), a sensitive marker of alternatively activated macrophages, and eosinophil-specific chemokines [4, 48]. The type 2 inflammation may result from lack of SHARPIN in stromal cells, immune cells, or both. To determine the effect of loss of Sharpin in non-immune cell types on expression of type 1 and type 2 cytokines, changes in various cytokine mRNA levels were evaluated in CMV, Krt14, and S100a4 Sharpin<sup>−/−</sup> mice, and appropriate controls.

The dermatitis in the skin of all mutant mice was associated with a highly significant (p < 0.0005) increased expression of Chil3 consistent with type 2 inflammation (S14 Fig). This was supported by the increase of Il4, Il5, and Il13 mRNA expression and decreased expression of Ifng except in the BALB-CMV Sharpin<sup>−/−</sup> mice (Fig 7). The change in cytokine expression was greatest in the B6-CMV Sharpin<sup>−/−</sup> mice and least in the S100a4 Sharpin<sup>−/−</sup> mice reflecting the severity of the inflammation observed by light microscopy. These data indicate that the selective deletion of SHARPIN in stromal cells did not change the type of inflammation.

We previously reported increased expression of the epithelial cytokines thymic stromal lymphopoietin (TSLP) and IL33 in the skin of Sharpin<sup>cpdm/cpdm</sup> mice [6]. There was significant increase of Tslp and Il33 mRNA in the skin of CMV Sharpin<sup>−/−</sup> mice, but only an increase of Tslp mRNA and not Il33 mRNA in the skin of Krt14 Sharpin<sup>−/−</sup> mice (Fig 7).

CCL11 (eotaxin) and CCL24 (eotaxin-2) are two eosinophil-specific chemokines that attract eosinophils into tissues and can induce their activation. We observed significantly

---

**Fig 6. Serum IL18.** Concentration of IL18 in the serum of (A) WT and Sharpin<sup>cpdm</sup> mice (5–7 weeks of age, 6 mice/group), (B) Krt14 Sharpin<sup>−/−</sup> and control mice (4–6 mice/group) and (C) S100a4 Sharpin<sup>−/−</sup> and control mice (3–5 mice/group). Bars indicate the mean ± SEM. **p < 0.01; ***p < 0.001.

https://doi.org/10.1371/journal.pone.0235295.g006
increased expression of $Ccl11$ and $Ccl24$ mRNA in the skin of $B6$-$CMV$ $Sharpin^{-/-}$ mice, but only increased expression of $Ccl24$ mRNA in the skin of $B6$-$CMV$ and $Krt14$ $Sharpin^{-/-}$ mice. There was no significant increase in the expression of these chemokines in the skin of $S100a4$ $Sharpin^{-/-}$ mice (Fig 7).
There was a marked accumulation of mast cells in the skin of \textit{Sharpin}\textsuperscript{cpdm/cpdm} mice [1]. We examined the expression of mast cell protease genes. \textit{Mcpt4} and 5 are specifically expressed by connective tissue mast cells [61], and \textit{Mcpt8} by basophils [62]. Surprisingly, there was a significant, but modest increase of \textit{Mcpt4} and \textit{Mcpt5} mRNA in the skin of B6-CMV \textit{Sharpin}\textsuperscript{-/-} mice, but not in the skin of the other mutant mice. By contrast, the expression of \textit{Mcpt8} mRNA was increased significantly in all mutant mice. The mast cell protease 9, encoded by \textit{Mcpt9}, was initially reported to be selective expressed in uterine mast cells in mice [63], but is also expressed in mast cell lines derived from spleens [64]. The expression of \textit{Mcpt9} was increased in all mutant mice except for the S100a4 \textit{Sharpin}\textsuperscript{-/-} mice (Fig 7).

**Discussion**

Correlating the specific cell types in which a gene is highly expressed and its biological function is not always straightforward. For example, the ATP-binding cassette, sub-family C (CFTR/MPR), member 6 (\textit{Abcc6}) gene is normally highly expressed in the liver and to a lesser extent in the kidney, yet lesions, ectopic mineralization in this case, occur at other anatomical sites [65]. In this case, the ABCG6 protein acts as a transmembrane ATP efflux transporter. In other cases, genes can be highly expressed in locations where lesions occur when they are mutated, such as stearoyl-Coenzyme A desaturase 1 (\textit{Scd1}), which regulates lipid metabolism and results in severe abnormalities in sebaceous glands when missing [66]. In the case of the \textit{Sharpin} gene, immortalized mouse embryonic fibroblasts have been used extensively to define its biochemical functions yet the data generated has not always matched experimental results using live mice carrying spontaneous null mutations in the gene as indicated in the introduction. Primary cultures of human keratinocytes as well as mouse keratinocytes and embryonic fibroblasts have been used to study the effect of SHARPIN deficiency on TNF-induced apoptosis [12–16]. SHARPIN-deficiency leads to increased sensitivity of these cells as well as myeloid cells to TNF-induced cell death [16]. Systemic deletion of TNFR1 prevented both the dermatitis and inflammation in the liver and lungs [14, 15]. However, specific deletion of TNFR1 in keratinocytes prevented keratinocyte cell death and dermatitis, but did not ameliorate systemic inflammation [15]. Both keratinocyte and systemic cell death and inflammation are dependent on enzymatically active RIPK1 [67]. By contrast, RIPK3 and MLKL-deficiency had no effect on the dermatitis, but greatly reduced systemic inflammation [16]. This indicates cell and tissue type-specific effects and mechanisms of TNF-induced cell death caused by deficiency of SHARPIN. To begin to address the role of SHARPIN in specific cell types, a conditional \textit{Sharpin} null mouse was created. Mutant mice were crossed with transgenic strains carrying promoters that drove \textit{cre}-recombinase expression ubiquitously throughout the body, which would recapitulate the spontaneous \textit{Sharpin} null allele phenotypes, or ones that expressed \textit{cre} in keratinocytes (\textit{Krt14}), fibroblasts (S100a4), or adipocytes (\textit{Adipoq}).

Inbred, congenic, hybrid, or mixed genetic backgrounds often have major effects on single gene mutations that have a major effect on the health of the mouse which reflects effects of various modifier genes in one strain versus another [68]. Lack of large-scale standardization of strain background used to make many of the \textit{cre}-recombinases can be a problem in some studies as was in this one. A differential effect in disease severity was observed with two different spontaneous allelic mutations in \textit{Sharpin} where both were functional null alleles, one on a B6 substrain and the other on a BALB congenic strain, the latter being more severely affected [6]. To recapitulate this, B6- and BALB-CMV-\textit{cre}-recombinases transgenic mice were crossed with the B6.Cg conditional \textit{Sharpin} allele. This was initially set up using the BALB allele as it was the only one available at the time. When the B6 allele became available, it was used. Both had similar lesions at the gross, hematological, and histopathological levels; however, the B6 strain
was more severely affected than the BALB, opposite that of the spontaneous null alleles of *Sharpin*. These results limited comparative studies at older ages. Since the overall disease was the same with only differences in life expectancy, identification of modifier genes could be relatively difficult. Alternatively, the effect of the *Sharpin* null mutation is quite severe and overriding more subtle differences in phenotyping. This observation allows one to be less concerned about strain background in the crosses used in this study than in other studies where background effects play a major role.

Restricting the loss of SHARPIN expression to specific cell types resulted in different phenotypes. Absence of SHARPIN expression in adipocytes did not result in an abnormal phenotype. By contrast, skin disease was severe in the ubiquitously and keratin (*Krt14*) inactivated *Sharpin* and mild in the *S100a4 Sharpin*−/− cross. Verification of the expression of *S100a4-cre*-recombinase revealed that it was expressed in keratinocytes, albeit less so than for the *Krt14-cre*, but not in skin fibroblasts. While *S100A4* is still sometimes published as fibroblast-specific protein [54], results shown here reveal this is not the case, rather it is expressed in the epidermal and infundibular keratinocytes. This is also the case in human skin where *S100A4* is expressed in the hair follicle, Langerhans cells, and melanocytes [69, 70]. The gene/protein name has been changed to *S100 calcium binding protein A4* in Mouse Genome Informatics (http://www.informatics.jax.org; 22 Jan 2020). *S100a4-cre*-recombinase expression in keratinocytes explains why lesions were present in the skin. Reduced expression of the *cre*-recombinase in the mouse skin for the *S100a4* versus the *Krt14* may explain the qualitative and quantitative differences between these two crosses. While lesions were observed in mice of both sexes at relatively the same levels, in the *S100a4 Sharpin*−/− joint lesions were more severe than in the other crosses and more severe in the females. The knee joint was less often affected or less severely affected in males. Shoulder joints were more severely affected. *S100A4* is involved in promoting cancer progression and metastasis, fibrosis, inflammation, immune response, neuroprotection, angiogenesis, and some common non-tumor diseases including being upregulated in cells infiltrating rheumatoid arthritis synovial tissue [71, 72]. Images on the cre-recombinase website (http://www.informatics.jax.org/recombinase/specificity?id=MGI:3712292&system=skeletal+system; 6 Feb 2020) reveal that *S100a4* is expressed in bone and bone marrow which helps to partially explain the joint specific lesions in these mice. Two factors were probably involved in the variability in arthritis between individuals. One is that inbred strains could not be used as the *cre*-recombinase transgenic mice were not on the same background or were mixed backgrounds. This alone results in phenotypic variability. The second was that since some of the crosses were very detrimental, all mice were evaluated at 6 weeks of age as that was the only age at which representative mutant mice could be obtained from all the crosses. Lesions developed more consistently with age in those that were destined to develop lesions in affected organs, especially in the joints. This work needs to be repeated in detail to determine what cell types in the bone marrow and joints that express *S100a4*. This cross provides a useful model for studying autoinflammatory arthritis. These observations combined with protein localization using immunohistochemistry support keratinocytes as the primary cell type involved in many of the lesions, particular the skin.

The dermatitis in *Sharpin*<sup>cpdm/cpdm</sup> mice has many features in common with atopic dermatitis, but is not associated with an increase of serum IgE [3]. Indeed, previous work demonstrated that the dermatitis develops in the absence of functional B and T cells [6]. Mutant *Sharpin*<sup>cpdm/cpdm</sup> mice have decreased or undetectable serum IgG, IgA, and IgE and a modest increase of serum IgM [3]. This indicates a defect in isotype switching consistent with the impairment of NFκB signaling upon activation of B cells with anti-CD40 [12–14]. Remarkably, selective deletion of *Sharpin* in keratinocytes is sufficient to recapitulate the dermatitis of mice with the spontaneous *Sharpin* mutation, and this was associated with a marked increase of
serum IgE as the B cells in Krt14 Sharpin−/− mice were able to undergo isotype switching. The mechanism that underlies the increase of serum IgE is not entirely clear, but it likely involves increased secretion of IL18. The serum concentration of IL18 was increased dramatically in Krt14 Sharpin−/− mice. Transgenic mice with overexpression of IL18 in the epidermis develop a type 2 inflammatory dermatitis and increase of serum IgE [73]. In the absence of STAT6, required for signaling through the IL4 and IL13 receptor, these mice had undetectable IgE, but developed a similar dermatitis indicating that the IgE was not necessary for the development of the dermatitis. A direct role for IL18 in the increase of IgE is further supported by the observation that daily injection of IL18 induces an increase of serum IgE in an IL4-dependent manner [58]. An increase of serum IL18 has also been observed in human patients with atopic dermatitis and it has been suggested that IL18 can serve as a biomarker of disease severity [74].

TSLP and IL33 can be secreted by epithelial cells upon damage or stress and induce local inflammation through the activation of dendritic cells, type 2 innate lymphoid cells (ILC2), basophils, and mast cells [75]. Both Tslp and Il33 mRNA were increased in the skin of BALB- and B6-CMV Sharpin−/− mice, but only Tslp mRNA was increased in the skin of Krt14 Sharpin−/− and S100a4 Sharpin−/− mice. TSLP and IL33 both play a role in the induction of atopic dermatitis-like skin lesions following topical application of the vitamin D analogue calcipotriol [76, 77], and overexpression of TSLP and IL33 in the epidermis of transgenic mice induced a type 2 inflammatory response with accumulation of mast cells, eosinophils, and an increase of serum IgE [78, 79]. The expression of TSLP and IL33 is increased in the skin of human patients with atopic dermatitis [80, 81]. The dermatitis in SHARPIN-deficient mice is associated with apoptosis of keratinocytes [1]. The apoptosis and dermatitis were inhibited by deletion of TNFR1 [15, 16, 82]. This suggests that keratinocyte damage in the absence of SHARPIN may lead to release of TSLP and IL33, which initiate the dermatitis through the activation of ILC2 and basophils.

CCL11 and CCL24 are both ligands of the chemokine receptor CCR3 expressed on eosinophils and are involved in the recruitment and activation of eosinophils [83]. They are both secreted by fibroblasts upon stimulation with IL4 and IL13, but they have overlapping but distinct expression patterns and functions. Using genetically engineered mice, it was demonstrated that CCL24 had a dominant role in the recruitment of eosinophils into the airways of mice in an asthma model [84]. The expression of CCL24 was more consistently and strongly increased compared with CCL11 in the skin of mutant mice suggesting a more important role for CCL24 in the dermatitis of SHARPIN-deficient mice.

The dermatitis in mutant SharpinPdm/cpdm mice is characterized by a marked increase of the number of mast cells. It was therefore surprising that the expression of mast cell proteases Mcpt4 and Mcpt5, expressed in dermal connective tissue mast cells [61], was not or only minimally increased in the skin of mutant mice. However, treatment of bone marrow-derived mast cells with IL4 decreased the expression of Mcpt4 [85], suggesting that the expression of mast cell proteases is affected by the cytokines in a type 2 inflammatory environment. The mast cell protease 9 was initially reported to be exclusively expressed in mast cells isolated from the uterus in mice [63]. However, it can be expressed by other mast cells [64], and we show here that its expression is increased in the skin of mutant mice with dermatitis. The mast cell protease 8 is used as a marker of basophils based on the exclusive expression in these cells [62], although a report suggests that it is also expressed in granulocyte-macrophage progenitor cells [86]. Nevertheless, in the skin Mcpt8 expression is associated with basophils, and the marked increased expression of Mcpt8 suggests an increased number of basophils in the skin. Both TSLP and IL33 enhance the production and activation of basophils [87, 88].

Spontaneous Sharpin mutations that arose in laboratory mice [2] provided useful models to dissect linear ubiquitin chain assembly complex (LUBAC) which is required for activation of
the NFkB signaling pathway [12–14, 89] and they continue to do so [16, 27, 30, 34, 90]. The conditional Sharpin null allele, which is publicly available at The Jackson Laboratory, provides a new tool to further investigate this molecular pathway. Refining the mouse model, especially using the S100a4-cre-recombinase transgenic mouse, provides tools to investigate autoinflammatory arthritis and atopic dermatitis.

Supporting information

S1 Fig. Cre-recombinase expression for the different promotors used. Krt14-cre was expressed throughout the epidermis and hair follicles (A). S100A4-cre, which was expected to be limited to fibroblasts, was strongly expressed in keratinocytes of the epidermis and parts of the hair follicle (B). Adipoq-cre expression was limited to white and brown adipose tissue (C). (TIF)

S2 Fig. Change in body weight by cross. Males were consistently heavier than females. Mice with severe skin or skin and visceral lesions had moderate to severe weight loss as they aged. (TIF)

S3 Fig. Peripheral blood values. White blood cells in peripheral blood of wild-type (WT), Krt14 Sharpin<sup>+/−</sup> (Krt14-Sharpin), and S100a4 Sharpin<sup>−/−</sup> (S100a4-Sharpin) mice. Bars represent the mean ± SEM. * P < 0.05; ** P < 0.01. (TIF)

S4 Fig. Limiting ridge and forestomach histology. The normal forestomach of mice is lined by stratified squamous epithelium. The epithelium forms a papillomatous structure, stratified squamous epithelium on a fibrovascular stalk, called the limiting ridge that forms a junction with the glandular stomach. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin<sup>+/−</sup>) (C, D) had lesions identical to the spontaneous Sharpin<sup>cpdm/cpdm</sup> mice (B). The squamous epithelia were moderately to severely acanthotic with orthokeratotic hyperkeratosis and moderate apoptosis of keratinocytes, very similar to epidermal changes in affected mice. While KRT14 is expressed in the forestomach by immunohistochemistry (data not shown) similar to where SHARPIN is expressed (Fig 2N) the forestomach was normal in the Krt14-cre mice (E). Mice carrying the S100a4-cre (F) or Adipoq-cre (G) all had normal forestomach anatomy. Low magnification 100X, high magnification 400X. (TIF)

S5 Fig. Liver histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin<sup>+/−</sup>) (C, D) had lesions identical to the spontaneous Sharpin<sup>cpdm/cpdm</sup> mice (B). A mixed inflammatory cell infiltrate was present surrounding large hepatic veins and portal triads. Fibrosis was a feature of the inflammation around large veins. Mice carrying the Krt14-cre (E), S100a4-cre (F), or Adipoq-cre (G) all had normal livers. Low magnification 40X, high magnification 40X. (TIF)

S6 Fig. Lung histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin<sup>+/−</sup>) (C, D) had lesions identical to the spontaneous Sharpin<sup>cpdm/cpdm</sup>
There was a mixed inflammatory cell infiltrate around the bronchioles and pulmonary veins. Mice that were Krt14 (E), S100a4 (F), or Adipoq Sharpin+/− (G) all had normal lungs. Low magnification 40X, high magnification 400X.

**S7 Fig. Shoulder joint.** Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin+/−) (C, D) had lesions similar to but less severe than in the spontaneous Sharpin^{cpdm/cpdm} mice (B). The soft tissue surrounding the joint capsule had mild infiltration by granulocytes. Granulocytes and fibrin were present within the joint space. Severity varied between individuals with some males having more severe lesions. Krt14 Sharpin+/− mice were normal (E). S100a4 Sharpin+/− consistently had severe lesions (F). Adipoq Sharpin+/− mice were unaffected. Low magnification 40X, high magnification 400X.

**S8 Fig. Knee joint histology.** Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin+/−) (C, D) had lesions identical to the spontaneous Sharpin^{cpdm/cpdm} mice (B). The soft tissue surrounding the joint capsule had mild infiltration by granulocytes. Granulocytes were present within the joint space but were few in number. Krt14 (E) and Adipoq Sharpin+/− (G) joints were unaffected. However, joint lesions were more prominent and severe in the S100a4-cre mice (F) but less so than in the knee or temporomandibular joints. Low magnification 40X, high magnification 400X.

**S9 Fig. Middle ear histology.** Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A) having middle ears with no evidence of inflammation. By contrast, mice homozygous for the spontaneous Sharpin^{cpdm/cpdm} mutation consistently had moderate to severe mixed inflammatory cells in the middle ear and surrounding soft tissues (B). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin+/−) (C, D) also had middle ear inflammation. Mice carrying the Krt14 (E), S100a4 (F), or Adipoq Sharpin+/− (G) all had normal, unaffected, middle ears. Low magnification 40X, high magnification 400X.

**S10 Fig. Peyer’s patch histology.** Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A) having Peyer’s patches in their small intestines. Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the conditional Sharpin gene (Sharpin+/−) (C, D) had lesions identical to the spontaneous Sharpin^{cpdm/cpdm} mice (B). At this age either there was no evidence of Peyer’s patches (C, D) or remnants effaced by eosinophils (B, high mag). Mice carrying the Krt14 (E), S100a4 (F), or Adipoq Sharpin+/− (G) all had normal Peyer’s patches. Low magnification 40X, high magnification 400X.

**S11 Fig. Spleen histology.** Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice carrying one or two copies of the ubiquitously expressing CMV-cre and homozygous for the
conditional Sharpin gene (Sharpin\(^{-}\)) (C, D) had lesions identical to the spontaneous Sharpin\(^{cpdm/cpdm}\) mice (B). In all 3 of these groups the spleen had severely disrupted white pulp microarchitecture. There was no separate T- and B-cell areas, lack of follicles, marginal zone, and follicular dendritic cells [91]. Mice carrying the Krt14 (E), S100a4 (F), or Adipoq (G) all had normal spleens. Low magnification 40X, high magnification 400X.

(S12 Fig. Cervical lymph node histology. Female mice, 6 weeks of age, carrying any of the cre-recombinase transgenes but no or only one copy of the conditional Sharpin gene were normal (A). Mice homozygous for the spontaneous chronic proliferative dermatitis (Sharpin\(^{cpdm/cpdm}\)) null mutation had marked lymphoid depletion with effacement of the lymph node by eosinophils (B). Mice carrying one or two copies of the ubiquitously expressing CMV-cre on either the BALB (C) or B6 (D) background and homozygous for the conditional Sharpin gene (Sharpin\(^{-}\)) had lesions identical to the spontaneous Sharpin\(^{cpdm/cpdm}\) mice (B). All lymph nodes throughout the body were similarly affected. The cortex and follicles were missing, effaced by a population of granulocytes that were primarily eosinophils. Occasionally areas of the medulla had fibrin deposition and necrosis in the regions where follicles are usually found, as shown for Sharpin\(^{cpdm/cpdm}\) (B, higher magnification). Mice carrying the Krt14 (E), S100a4 (F), or Adipoq Sharpin\(^{-}\) (G) all had normal lymph nodes throughout the body. Low magnification 40X, high magnification 400X.

(S13 Fig. Serum immunoglobulins in 5–7 week old WT and Sharpin\(^{cpdm/cpdm}\) mice. Bars represent the mean ± SE of 6 mice/group. * p < 0.05.

(S14 Fig. Expression of mRNA of Chil3 in wild type (WT) and the indicated mutant mice. Bars represent the mean + SEM of fold change in gene expression in mutant vs. WT mice. *** P < 0.001.

(S15 Fig. Original uncropped and unadjusted images underlying results reported in Fig 1.

Acknowledgments

The authors thank Zoe Reifsnyder for assistance with the figures and Nicholas E. Gott in the Histopathology Scientific Service for performing the histology and immunohistochemistry.

Author Contributions

Conceptualization: John P. Sundberg, Leslie P. Goodwin, Harm HogenEsch.

Formal analysis: John P. Sundberg, Christopher S. Potter, Beth A. Sundberg, Harm HogenEsch.

Funding acquisition: John P. Sundberg, Harm HogenEsch.

Investigation: John P. Sundberg, Kathleen A. Silva, Victoria E. Kennedy, Christopher S. Potter, Anisa Dunham, Harm HogenEsch.

Methodology: John P. Sundberg, Harm HogenEsch.

Project administration: John P. Sundberg, Harm HogenEsch.
Resources: John P. Sundberg, Leslie P. Goodwin, Harm HogenEsch.

Supervision: John P. Sundberg, Harm HogenEsch.

Validation: John P. Sundberg, Harm HogenEsch.

Writing – original draft: John P. Sundberg, C. Herbert Pratt, Harm HogenEsch.

Writing – review & editing: John P. Sundberg, C. Herbert Pratt, Leslie P. Goodwin, Kathleen A. Silva, Victoria E. Kennedy, Christopher S. Potter, Anisa Dunham, Beth A. Sundberg, Harm HogenEsch.

References

1. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol. 1993; 143(3):972–82. PMID: 8362989; PubMed Central PMCID: PMC1887192.

2. Seymour RE, Hasham MG, Cox GA, Shultz LD, Hogenesch H, Roopenian DC, et al. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 2007; 8(5):416–21. https://doi.org/10.1038/sj.gene.6364403 PMID: 17538631.

3. Hogenesch H, Janke S, Boggess D, Sundberg JP. Absence of Peyer’s patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J Immunol. 1999; 162(7):3890–6. PMID: 10201907.

4. Hogenesch H, Torregrosa SE, Boggess D, Sundberg BA, Carroll J, Sundberg JP. Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12. Eur J Immunol. 2001; 31(3):734–42. https://doi.org/10.1002/1521-4141(200103)31:3<734::aid-immu734>3.0.co;2-9 PMID: 11241277.

5. Seymour R, Shirley BJ, Hogenesch H, Shultz LD, Sundberg JP. Loss of function of the mouse Sharpin gene results in Peyer’s patch regression. PloS one. 2013; 8(2):e55224. https://doi.org/10.1371/journal.pone.0055224 PMID: 23424642; PubMed Central PMCID: PMC3570409.

6. Potter CS, Wang Z, Silva KA, Kennedy VE, Stearns TM, Burzenski L, et al. Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL-4/IL13 signaling. PloS one. 2014; 9(1):e85666. https://doi.org/10.1371/journal.pone.0085666 PMID: 24465642; PubMed Central PMCID: PMC3402681.

7. Wang Z, Potter CS, Sundberg JP, Hogenesch H. SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med. 2012; 16(10):2271–9. https://doi.org/10.1111/j.1582-4934.2012.01574.x PMID: 22452937; PubMed Central PMCID: PMC3402681.

8. Sasaki K, Iwai K. Roles of linear ubiquitylation, a crucial regulator of NF-kappaB and cell death, in the immune system. Immunol Rev. 2015; 266(1):175–89. https://doi.org/10.1111/imr.12308 PMID: 26085215.

9. Rittinger K, Ikeda F. Linear ubiquitin chains: enzymes, mechanisms and biology. Open Biol. 2017; 7(4). https://doi.org/10.1098/rsob.170026 PMID: 28446710; PubMed Central PMCID: PMC5413910.

10. Lim S, Sala C, Yoon J, Park S, Kuroda S, Sheng M, et al. Sharpin, a novel postsynaptic density protein that directly interacts with the Shank family of proteins. Mol Cell Neurosci. 2001; 17(2):385–97. https://doi.org/10.1006/mcne.2000.0940 PMID: 11178875.

11. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009; 36(5):831–44. https://doi.org/10.1016/j.molcel.2009.10.013 PMID: 20005846.

12. Ikeda F, Deribe YL, Skandlan SS, Steiglitz B, Grabbe C, Franz-Wachtel M, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature. 2011; 471(7340):637–41. https://doi.org/10.1038/nature09814 PMID: 21455181; PubMed Central PMCID: PMC3085511.

13. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature. 2011; 471(7340):633–6. https://doi.org/10.1038/nature09815 PMID: 21455190.

14. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011; 471(7340):591–6. https://doi.org/10.1038/nature09816 PMID: 21455173.
15. Kumari S, Redouane Y, Lopez-Mosqueda J, Shiraishi R, Romanowska M, Lutzmayer S, et al. SHARPIN deficiency prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. Elife. 2014; 3. https://doi.org/10.7554/elife.03422 PMID: 25443631; PubMed Central PMCID: PMC4225491.

16. Rickard JA, Anderton H, Etemad N, Nachbaur U, Darding M, Peltzer N, et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife. 2014; 3. https://doi.org/10.7554/elife.03464 PMID: 25443632; PubMed Central PMCID: PMC4270099.

17. Takiuchi T, Nakagawa T, Tamiya H, Fujita H, Sasaki Y, Seaki Y, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinas CYLD and OTULIN. Genes Cells. 2014; 19(3):254–72. https://doi.org/10.1111/gtc.12128 PMID: 24461064.

18. Elliott PR, Leske D, Hrdinka M, Bagola K, Fii BK, McLaughlin SH, et al. SPATA22 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell. 2016; 63(6):990–1005. https://doi.org/10.1016/j.molcel.2016.08.001 PMID: 27591049; PubMed Central PMCID: PMC5031558.

19. Kupka S, De Miguel D, Rittinger K, et al. SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. Cell Rep. 2016; 16(9):2271–80. https://doi.org/10.1016/j.celrep.2016.07.086 PMID: 27545878; PubMed Central PMCID: PMC5009064.

20. Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med. 2015; 212(6):939–51. https://doi.org/10.1084/jem.20141130 PMID: 26008899; PubMed Central PMCID: PMC4541453.

21. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL1 and LUBAC deficiency. Nat Immunol. 2012; 13(12):1178–86. https://doi.org/10.1038/ni.2457 PMID: 23104095; PubMed Central PMCID: PMC3514453.

22. Nilsson J, Schoser B, Laforet P, Kalev O, Lindberg C, Romero NB, et al. Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1. Ann Neurol. 2013; 74(6):914–9. https://doi.org/10.1002/ana.23963 PMID: 23799481.

23. Wang K, Kim C, Bradfield J, Guo Y, Toskala E, Otieno FG, et al. Whole-genome DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian disease with neuromuscular and cardiac involvement. Genome Med. 2013; 5(7):67. https://doi.org/10.1186/gm471 PMID: 23889995; PubMed Central PMCID: PMC3971341.

24. Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR, et al. The Deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell. 2016; 166(5):1215–30 e20. https://doi.org/10.1016/j.cell.2016.07.019 PMID: 27523609; PubMed Central PMCID: PMC5002269.

25. Zhou Q, Yu X, Demirkaya E, Deutch N, Stone D, Tsai WL, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci USA. 2016; 113(36):10127–32. https://doi.org/10.1073/pnas.1612594113 PMID: 27559085; PubMed Central PMCID: PMC5018768.

26. Steiner A, Harapas CR, Masters SL, Davidson S. An Update on Autoinflammatory diseases: relapses. Curr Rheumatol Rep. 2018; 20(7):39. https://doi.org/10.1007/s11926-018-0749-x PMID: 29846841.

27. Gurung P, Sharma BR, Kanneganti TD. Distinct role of IL-1beta in instigating disease in Sharpin(pdpm) mice. Scientific Reports. 2016; 6:36634. https://doi.org/10.1038/srep36634 PMID: 27892465; PubMed Central PMCID: PMC5125001.

28. Rantala JK, Pouwels J, Pellinen T, Veitl T, Saasola P, Mattila E, et al. SHARPIN is an endogenous inhibitor of beta1-integrin activation. Nat Cell Biol. 2011; 13(11):1315–24. https://doi.org/10.1038/ncb2340 PMID: 21947080; PubMed Central PMCID: PMC3257806.

29. Pouwels J, De Franceschi N, Rantakari P, Auvinen K, Karikoski M, Mattila E, et al. SHARPIN regulates uropod detachment in migrating lymphocytes. Cell Rep. 2013; 5(3):619–28. https://doi.org/10.1016/j.celrep.2013.10.011 PMID: 24210817; PubMed Central PMCID: PMC3852511.

30. Sharma BR, Karki R, Lee E, Zhu Q, Gurung P, Kanneganti TD. Innate immune adaptor MyD88 deficiency prevents skin inflammation in SHARPIN-deficient mice. Cell Death Differ. 2019; 26(4):741–50. https://doi.org/10.1038/s41418-018-0159-7 PMID: 30038386; PubMed Central PMCID: PMC6460383.

31. Khan MH, Salomaa SJ, Jacquemet G, Butt U, Mihikinen M, Deguchi T, et al. The Sharpin interactome reveals a role for Sharpin in lamellipodium formation via the Arp2/3 complex. J Cell Sci. 2017; 130(18):3094–107. https://doi.org/10.1242/jcs.200329 PMID: 28775156; PubMed Central PMCID: PMC5612173.

32. Zingrebe J, Rieser E, Taraborelli L, Peltzer N, Hartwig T, Ren H, et al.—LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. J Exp Med. 2016; 213(12):2671–89. https://doi.org/10.1084/jem.20160041 PMID: 27810922; PubMed Central PMCID: PMC5110014.
33. Douglas T, Champagne C, Morizot A, Lapointe JM, Saleh M. The inflammatory caspases -1 and -11 mediate the pathogenesis of dermatitis in Sharpin-deficient Mice. J Immunol. 2015; 195(5):2365–73. https://doi.org/10.4049/jimmunol.1500542 PMID: 26216893.

34. Gurung P, Lamkanfi M, Kanneganti TD. Cutting edge: SHARPIN is required for optimal NLRP3 inflammasome activation. J Immunology. 2015; 194(5):2064–7. https://doi.org/10.4049/jimmunol.1402951 PMID: 25637014; PubMed Central PMCID: PMC4340749.

35. Brazee P, Dada LA, Sznajder J. Role of linear ubiquitination in health and disease. Am J Respir Cell Mol Biol. 2016; 54(6):761–8. https://doi.org/10.1165/rcmb.2016-0014TR PMID: 26848516; PubMed Central PMCID: PMC4942223.

36. Jung J, Kim JM, Park B, Cheon Y, Lee B, Choo SH, et al. Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 2010; 340(1–2):161–7. https://doi.org/10.1007/s11010-010-0413-x PMID: 20179993.

37. De Melo J, Tang D. Elevation of SIPL1 (SHARPIN) increases breast cancer risk. PloS one. 2015; 10(5): e0127546. https://doi.org/10.1371/journal.pone.0127546 PMID: 25992689; PubMed Central PMCID: PMC4438068.

38. Tanaka Y, Tateishi K, Nakatsuka T, Kudo Y, Takahashi R, Miyabayashi K, et al. Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis. 2016; 5(12):e277. https://doi.org/10.1038/oncsis.2016.76 PMID: 27941932; PubMed Central PMCID: PMC4777774.

39. Zhuang T, Yu S, Zhang L, Yang H, Li X, Hou Y, et al. SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation. Oncotarget. 2017; 8(44):77137–51. https://doi.org/10.18632/oncotarget.20368 PMID: 28903384

40. Ojo D, Selman M, Tang D. Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer. BBA Clin. 2017; 8:56–65. https://doi.org/10.1016/j.bacak.2017.07.004 PMID: 28879097; PubMed Central PMCID: PMC5582379.

41. Ojo D, Selman M, Tang D. Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer. BBA Clin. 2017; 8:56–65. https://doi.org/10.1016/j.bacak.2017.07.004 PMID: 28879097; PubMed Central PMCID: PMC5582379.

42. Liu P, Jenkins NA, Copeland NG. A highly efficient recombinase-based method for generating conditional knockout mutations. Genome Res. 2003; 13(3):476–84. https://doi.org/10.1101/gr.749203 PMID: 12618380; PubMed Central PMCID: PMC4473866.

43. Liu P, Jenkins NA, Copeland NG. A highly efficient recombinase-based method for generating conditional knockout mutations. Genome Res. 2003; 13(3):476–84. https://doi.org/10.1101/gr.749203 PMID: 12618380; PubMed Central PMCID: PMC4473866.

44. Silva K, Sundberg JP. Necropsy methods. In: Hedrich HJ, editor. The laboratory mouse. Second edition / ed. Amsterdam: AP, Elsevier; 2012. p. 779–806 p.

45. Sundberg JP, Sundberg BA, Schofield P. Integrating mouse anatomy and pathology ontologies into a phenotyping database: tools for data capture and training. Mam Genome. 2008; 19(6):413–9. https://doi.org/10.1038/sj.mmg.1301517 PMID: 18797968; PubMed Central PMCID: PMC2844541.

46. Renninger ML, Seymour R, Lillard JW Jr., Sundberg JP, HogenEsch H. Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice. Exp Dermatol. 2005; 14(12):906–13. https://doi.org/10.1111/j.1600-0625.2005.00378.x PMID: 16274458.

47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25(4):402–8. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609.

48. Heffner CS, Herbert Pratt C, Babiuk RP, Sharma Y, Rockwood SF, Donahue LR, et al. Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource. Nature Com. 2012; 3:1218. https://doi.org/10.1038/ncomms1218 PMID: 23169059; PubMed Central PMCID: PMC3514490.

49. Bolon B. Whole mount enzyme histochemistry as a rapid screen at necropsy for expression of beta-galactosidase (LacZ)-bearing transgenes: considerations for separating specific LacZ activity from
nonspecific (endogenous) galactosidase activity. Toxicol Pathol. 2008; 36(2):265–76. https://doi.org/10.1177/0192633707312693 PMID: 18369090.

52. Renninger ML, Seymour RE, Whiteley LO, Sundberg JP, Hogenesch H. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient mice. Exp Dermatol. 2010; 19(3):252–8. https://doi.org/10.1111/j.1600-0625.2009.00944.x PMID: 19650867; PubMed Central PMCID: PMC2852468.

53. Sundberg JP, Steams TM, Joh J, Proctor M, Ingle A, Silva KA, et al. Immune status, strain background, and anatomic site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic papillomas or endophytic trichoblastomas. PLoS one. 2014; 9(12):e113582. https://doi.org/10.1371/journal.pone.0113582 PMID: 25474466; PubMed Central PMCID: PMC4256377.

54. Louka ML, Ramzy MM. Involvement of fibroblast-specific protein 1 (S100A4) and matrix metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver fibrosis. Gene. 2016; 579(1):29–33. https://doi.org/10.1016/j.gene.2015.12.042 PMID: 26721462.

55. Gijsbels MJ, Zurcher C, Kraai G, Elliott GR, HogenEsch H, Schijff G, et al. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm). Am J Pathol. 1996; 148(3):941–50. PMID: 8774148; PubMed Central PMCID: PMC1861706.

56. Hogenesch H, Sola M, Steams TM, Silva KA, Kennedy VE, Sundberg JP. Angiogenesis in the skin of SHARPIN-deficient mice with chronic proliferative dermatitis. Exp Mol Pathol. 2016; 101(3):303–7. https://doi.org/10.1016/j.yexmp.2016.05.015 PMID: 27794420; PubMed Central PMCID: PMC5164954.

57. Chien SJ, Silva KA, Kennedy VE, HogenEsch H, Sundberg JP. The pathogenesis of chronic eosinophilic esophagitis in SHARPIN-deficient mice. Exp Mol Pathol. 2015; 99(3):460–7. https://doi.org/10.1016/j.yexmp.2015.08.012 PMID: 26321248; PubMed Central PMCID: PMC4679700.

58. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamakawa K, Tanaka M, et al. IL-18 induction of IgE dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol. 2000; 1(2):132–7. https://doi.org/10.1038/77811 PMID: 11248805.

59. Li Q, Kingman J, van de Wetering K, Tannouiri S, Sundberg JP, Uitto J. Dermatitis-associated fibroblast growth factor 1 regulates expression of matrix metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver fibrosis. Gene. 2016; 579(1):29–33. https://doi.org/10.1016/j.gene.2015.12.042 PMID: 26721462.

60. Poorafshar M, Helmby H, Troye-Blomberg M, Hellman L. MMCP-8, the first lineage-specific differentiation marker for mouse basophils. Elevated numbers of potent IL-4-producing and MMCP-8-positive cells in spleens of malaria-infected mice. Eur J Immunol. 2000; 30(9):2660–8. https://doi.org/10.1002/1521-4141(200009)30:9<2660::AID-IMMU2660>3.0.CO;2-I PMID: 11009100.

61. Hunt JE, Friend DS, Gurish MF, Feylant E, Sali A, Huang C, et al. Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells. J Biol Chem. 1997; 272(46):29158–66. https://doi.org/10.1074/jbc.272.46.29158 PMID: 9360993.

62. Trzcinski M, Glen J, Bandurski T, Sokolowska-Wojdylo M, Wilkowska A, Roszkiewicz J. Relationship between serum levels of interleukin-18, IgE and disease severity in patients with atopic dermatitis. Clin Exp Dermatol. 2011; 36(7):728–32. https://doi.org/10.1111/j.1365-2230.2011.04113.x PMID: 21689145.

63. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol. 2007; 95:167–255. https://doi.org/10.1016/S0065-2776(07)95006-3 PMID: 17869614.

64. Li Q, Kingman J, van de Wetering K, Tannouiri S, Sundberg JP, Uitto J. Abcc6 knockout rat model highlights the role of liver in PPI homeostasis in pseudoxanthoma elasticum. J Invest Dermatol. 2017; 137(5):1025–32. https://doi.org/10.1016/j.jid.2016.11.042 PMID: 28111219.

65. Sproule TJ, Bubier JA, Grandi FC, Sun VZ, Philip VM, McPhee CG, et al. Molecular identification of collagen 17α1 as a major genetic modifier of laminin gamma 2 mutation-induced junctional epidermolysis bullosa in mice. PLoS genetics. 2014; 10(2):e1004068. https://doi.org/10.1371/journal.pgen.1004068 PMID: 24550734; PubMed Central PMCID: PMC3923665.
69. Zhu L, Okano S, Takahara M, Chiba T, Tu Y, Oda Y, et al. Expression of S100 protein family members in normal skin and sweat gland tumors. J Dermatol Sci. 2013; 70(3):211–9. https://doi.org/10.1016/j.jdermsci.2013.03.002 PMID: 23623205.

70. Mitoma C, Kohda F, Mizote Y, Mieake A, Ijichi A, Kawahara S, et al. Localization of S100A5, S100A6, S100A7, and S100P in the human hair follicle. Fukuoka Igaku Zasshi. 2014; 105(7):148–56. PMID: 25507257.

71. Fei F, Qu J, Li C, Wang X, Li Y, Zhang S. Role of metastasis-induced protein S100A4 in human non-tumor-pathophysiology. Cell Biosci. 2017; 7:64. https://doi.org/10.1186/s13578-017-0191-1 PMID: 29204268; PubMed Central PMID: PMC5702147.

72. Klingelhofer J, Senolt L, Baslund B, Nielsen GH, Skibshoj I, Pavelka K, et al. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2007; 56(3):779–89. https://doi.org/10.1002/art.22398 PMID: 17320805.

73. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, Tanaka M, et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci USA. 2002; 99(17):11340–. https://doi.org/10.1073/pnas.152337799 PMID: 12151598; PubMed Central PMID: PMC123258.

74. Thijs JL, Nierkens S, Herath A, Bruijnzeel-Koomen CA, Knol EF, Giovannone B, et al. A panel of biomarkers for disease severity in atopic dermatitis. Clin Exp Allergy. 2015; 45(3):698–701. https://doi.org/10.1111/cea.12486 PMID: 25598986.

75. Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015; 43(1):29–40. https://doi.org/10.1016/j.immuni.2015.07.007 PMID: 26200011.

76. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33 in the regulation of type 2 immune responses in atopic dermatitis. Sci Transl Med. 2013; 5 (170):170ra16. https://doi.org/10.1126/scitranslmed.3005374 PMID: 23363980; PubMed Central PMCID: PMC3865470.

77. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013; 5 (170):170ra16. https://doi.org/10.1126/scitranslmed.3005374 PMID: 23363980; PubMed Central PMCID: PMC3865470.

78. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoi etin transgene specifically in the skin. J Exp Med. 2005; 202(4):541–9. https://doi.org/10.1084/jem.20041503 PMID: 16103410; PubMed Central PMID:PMC2212851.

79. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. J Exp Med. 2013; 210(13):2939–50. https://doi.org/10.1084/jem.20130351 PMID: 24323357; PubMed Central PMID: PMC3865470.

80. Pushparaj PN, Tay HK, H'Ng SC, Pitman N, Xu D, McKenzie A, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009; 106(24):9773–8. https://doi.org/10.1073/pnas.0901206106 PMID: 19506243; PubMed Central PMID: PMC2700978.

81. Soumelis V, Reche PA, Kanzier H, Yuan W, Edward G, Homey B, et al. Human epithelial cell triggers dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673–80. https://doi.org/10.1038/ni805 PMID: 12055625.

82. Eklund KK, Ghildyal N, Austen KF, Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of anaphylaxis and eosinophilic pulmona ry disease. J Immunol. 1993; 151(8):5341–50. PMID: 7691943.

83. Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting Tissue specific deletion of SHARPIN.

PMC5947819.

84. Pope SM, Zimmermann N, Stringer KE, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol. 2005; 175 (8):5341–50. https://doi.org/10.4049/jimmunol.175.8.5341 PMID: 1620640.

85. El Hachem C, Hener P, Kirstetter P, Li J, Chan S, Li M. Treatment of MCPT8(DTR) mice with high- or low-dose diphtheria toxin leads to differential depletion of basophils and granulocytic-macrophage pro-genitors. Eur J Immunol. 2018; 48(5):861–73. https://doi.org/10.1002/eji.201747351 PMID: 2931553.

86. Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting Tissue specific deletion of SHARPIN.

PMC5947819.

87. Pope SM, Zimmermann N, Stringer KE, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol. 2005; 175 (8):5341–50. https://doi.org/10.4049/jimmunol.175.8.5341 PMID: 1620640.

88. Eklund KK, Ghildyal N, Austen KF, Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell prote-as. J Immunol. 1993; 151(8):4266–73. PMID: 7691943.

89. El Hachem C, Hener P, Kirstetter P, Li J, Chan S, Li M. Treatment of MCPT8(DTR) mice with high- or low-dose diphtheria toxin leads to differential depletion of basophils and granulocytic-macrophage pro-genitors. Eur J Immunol. 2018; 48(5):861–73. https://doi.org/10.1002/eji.201747351 PMID: 2931553.
hematopoietic growth factor production. J Immunol. 2009; 183(6):3591–7. https://doi.org/10.4049/jimmunol.0900328 PMID: 19684081.

88. Siracusa MC, Saenz SA, Hill DA, Kim BS, Headley MB, Doering TA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature. 2011; 477(7363):229–33. https://doi.org/10.1038/nature10329 PMID: 21841801; PubMed Central PMCID: PMC3263308.

89. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 2009; 11(2):123–32. https://doi.org/10.1038/ncb1821 PMID: 19136968.

90. Shimizu S, Fujita H, Sasaki Y, Tsuruyama T, Fukuda K, Iwai K. Differential involvement of the Npl4 zinc finger domains of SHARPIN and HOIL-1L in linear ubiquitin chain assembly complex-mediated cell death protection. Mol Cell Biol. 2016; 36(10):1569–83. https://doi.org/10.1128/MCB.01049-15 PMID: 26976635; PubMed Central PMCID: PMC4859691.

91. Seymour R, Sundberg JP, Hogenesch J. Abnormal lymphoid organ development in immunodeficient mutant mice. Vet Pathol. 2006; 43(4):401–23. https://doi.org/10.1354/vp.43-4-401 PMID: 16846982.